Connect with us

Hi, what are you looking for?

Coronavirus

COVID Vaccine Spurs Good Response in People With Crohn’s, Colitis

New research finds vaccination triggers a strong immune reaction in people with Crohn’s Disease and Ulcerative Colitis.

Here’s some comforting news for people who struggle with inflammatory bowel disease and worry that the immune-suppressing drugs they must take might blunt their response to COVID-19 vaccines: New research finds vaccination triggers a strong immune reaction in these patients.

“At eight weeks, following completion of a two-dose mRNA vaccine series, 99% of patients had detectable antibodies from the vaccine, irrespective of whether or not they were receiving immunocompromising therapies,” said lead study author Dr. Gil Melmed. He is director of inflammatory bowel disease clinical research at Cedars-Sinai in Los Angeles.

Previous research has shown that other groups of patients receiving treatments that weaken their immune systems — such as transplant patients who take drugs to prevent organ rejection and cancer patients receiving chemotherapy — display much lower rates of antibody response to COVID-19 vaccines.

The new study was published recently in the Annals of Internal Medicine.

Ulcerative colitis and Crohn’s disease are two forms of inflammatory bowel disease (IBD), in which an abnormal immune response causes chronic and often destructive inflammation of the digestive tract. Many patients with IBD take medications to suppress their immune system.

The study did find that the antibody response in IBD patients differed at a certain point after receiving their second dose of COVID-19 vaccine, and the differences were due to the type of immunosuppressive medications they were taking.

According to co-principal investigator Dr. Dermot McGovern, “After eight weeks, we noted lower antibody levels in patients receiving anti-TNF (tumor necrosis factor) therapies or corticosteroids compared to patients treated with the immune-response blocking drugs anti-tegrin, anti-IL12/23.” McGovern is director of translational research at the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai.

“However,” he added, “these findings should still reassure IBD patients — and the millions of people who use these types of immunosuppressive medications — that the immediate response to mRNA vaccines against SARS-CoV-2, the virus that causes COVID-19, is good and on par with IBD patients who are not taking any drug therapies. Even so, patients receiving anti-TNF therapy or corticosteroids may be the ones most likely to benefit from a third dose of the vaccine.”

Overall, the IBD patients’ antibody response to COVID-19 vaccination was similar to that of people with healthy immune systems, the researchers noted.

Immunosuppressed patients are often viewed as a high-risk group. But, Melmed said, this “study shows that while there may be differences based on medication types, almost all IBD patients have positive responses to the mRNA vaccine.”

The researchers are now assessing other aspects of COVID-19 vaccine response in IBD patients more directly associated with protection from infection, such as T-cell function and neutralizing antibody responses.

More information

The Crohn’s & Colitis Foundation of America has more on IBD.

SOURCE: Cedars-Sinai, news release, Nov. 2, 2021

You May Also Like

Coronavirus

Hopes for an easing of the pandemic were dealt a major setback over the Thanksgiving weekend, with news that a variant first spotted in...

Coronavirus

A COVID-19 vaccine booster shot gives cancer patients — especially those with blood cancer — much-needed protection, new research reports. “Our study demonstrates in...

Coronavirus

Long COVID is rare in college athletes, but those who have had COVID-19 should see a doctor if they have chest pain during activity.

Coronavirus

Janice Blanchard, MD, PhD explains the difference between symptomatic and asymptomatic COVID. Black doctors, nurses and researchers dispel misinformation and provide accessible facts about...

News

COVID Vaccine Spurs Good Response in People With Crohn’s, Colitis

THURSDAY, Nov. 4, 2021 (HealthDay News) — Here’s some comforting news for people who struggle with inflammatory bowel disease and worry that the immune-suppressing drugs they must take might blunt their response to COVID-19 vaccines: New research finds vaccination triggers a strong immune reaction in these patients.

“At eight weeks, following completion of a two-dose mRNA vaccine series, 99% of patients had detectable antibodies from the vaccine, irrespective of whether or not they were receiving immunocompromising therapies,” said lead study author Dr. Gil Melmed. He is director of inflammatory bowel disease clinical research at Cedars-Sinai in Los Angeles.

Previous research has shown that other groups of patients receiving treatments that weaken their immune systems — such as transplant patients who take drugs to prevent organ rejection and cancer patients receiving chemotherapy — display much lower rates of antibody response to COVID-19 vaccines.

The new study was published recently in the Annals of Internal Medicine.

Ulcerative colitis and Crohn’s disease are two forms of inflammatory bowel disease (IBD), in which an abnormal immune response causes chronic and often destructive inflammation of the digestive tract. Many patients with IBD take medications to suppress their immune system.

The study did find that the antibody response in IBD patients differed at a certain point after receiving their second dose of COVID-19 vaccine, and the differences were due to the type of immunosuppressive medications they were taking.

According to co-principal investigator Dr. Dermot McGovern, “After eight weeks, we noted lower antibody levels in patients receiving anti-TNF (tumor necrosis factor) therapies or corticosteroids compared to patients treated with the immune-response blocking drugs anti-tegrin, anti-IL12/23.” McGovern is director of translational research at the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai.

“However,” he added, “these findings should still reassure IBD patients — and the millions of people who use these types of immunosuppressive medications — that the immediate response to mRNA vaccines against SARS-CoV-2, the virus that causes COVID-19, is good and on par with IBD patients who are not taking any drug therapies. Even so, patients receiving anti-TNF therapy or corticosteroids may be the ones most likely to benefit from a third dose of the vaccine.”

Overall, the IBD patients’ antibody response to COVID-19 vaccination was similar to that of people with healthy immune systems, the researchers noted.

Immunosuppressed patients are often viewed as a high-risk group. But, Melmed said, this “study shows that while there may be differences based on medication types, almost all IBD patients have positive responses to the mRNA vaccine.”

The researchers are now assessing other aspects of COVID-19 vaccine response in IBD patients more directly associated with protection from infection, such as T-cell function and neutralizing antibody responses.

More information

The Crohn’s & Colitis Foundation of America has more on IBD.

SOURCE: Cedars-Sinai, news release, Nov. 2, 2021

You May Also Like

Healthy Living

Older Black Americans are much more likely to have good hearing than white Americans, and the difference is especially notable among men, a new...

News

Several Old Spice and Secret aerosol spray antiperspirants and hygiene products have been voluntarily recalled in the United States due to the presence of...

News

U.S. cancer clinical trial participants have become more diverse in makeup, but certain groups remain underrepresented, a new study finds. It’s important to have...

Diet & Nutrition

Since before Americans officially celebrated Thanksgiving, turkey has had a place at the holiday table. Lately, it also has developed a reputation as a...

Get our wellness newsletter

Filter out the noise and nurture your inbox with health and wellness

advice that’s inclusive and rooted in medical expertise.